52-104 Week Off-therapy Second Extension to Study CSPP100A2365
Status:
Completed
Trial end date:
2017-08-03
Target enrollment:
Participant gender:
Summary
52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and
development in pediatric hypertensive patients previously treated with aliskiren in studies
SPP100A2365 and SPP100A2365E1